Duzhang Zhu
Overview
Explore the profile of Duzhang Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
290
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zlotnick G, Jones T, Liberator P, Hao L, Harris S, McNeil L, et al.
Hum Vaccin Immunother
. 2014 Dec;
11(1):5-13.
PMID: 25483509
Vaccines have had a major impact on the reduction of many diseases globally. Vaccines targeted against invasive meningococcal disease (IMD) due to serogroups A, C, W, and Y are used...
2.
Fernsten P, Mason K, Yu X, Tummolo D, Belanger K, Tsao H, et al.
Hum Vaccin
. 2011 Jan;
7 Suppl:75-84.
PMID: 21266856
PCV7 was first licensed in the United States in 2000 based on clinical efficacy studies. Since the introduction, PCV7 has demonstrated protective effectiveness for each of the vaccine serotypes. More...
3.
Harris S, Zhu D, Murphy E, McNeil L, Wang X, Mayer L, et al.
Hum Vaccin
. 2011 Jan;
7 Suppl:68-74.
PMID: 21245657
A bivalent factor H binding protein (fHBP) vaccine for the prevention of disease caused by Neisseria meningitidis serogroup B is currently in clinical development. Since fHBP is also expressed by...
4.
Jiang H, Hoiseth S, Harris S, McNeil L, Zhu D, Tan C, et al.
Vaccine
. 2010 Jul;
28(37):6086-93.
PMID: 20619376
Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein sequences segregate into two distinct subfamilies,...
5.
McNeil L, Murphy E, Zhao X, Guttmann S, Harris S, Scott A, et al.
Vaccine
. 2009 Feb;
27(25-26):3417-21.
PMID: 19200847
The outer membrane protein LP2086, a human factor H binding protein, is undergoing clinical trials as a vaccine against invasive serogroup B meningococcal (MnB) disease. As LP2086 is a surface...
6.
Nanra J, Timofeyeva Y, Buitrago S, Sellman B, Dilts D, Fink P, et al.
Vaccine
. 2009 Feb;
27(25-26):3276-80.
PMID: 19200819
There is a clear unmet medical need for a vaccine that would prevent infections from Staphylococcus aureus (S. aureus). To validate antigens as potential vaccine targets it has to be...
7.
Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G
Vaccine
. 2006 Apr;
24(26):5420-5.
PMID: 16621173
Neisseria meningitidis is a major cause of bacterial meningitis in the human population, especially among young children. There is a need to develop a non-capsular vaccine to prevent meningococcal B...
8.
Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G
Infect Immun
. 2005 Sep;
73(10):6838-45.
PMID: 16177362
Neisseria meningitidis is a major causative agent of bacterial meningitis in human beings, especially among young children (</=2 years of age). Prevention of group B meningococcal disease represents a particularly...
9.
Pillai S, Howell A, Alexander K, Bentley B, Jiang H, Ambrose K, et al.
Vaccine
. 2005 Mar;
23(17-18):2206-9.
PMID: 15755596
A family of outer membrane lipoproteins of Neisseria meningitidis, LP2086, has been shown to induce serum bactericidal activity against a broad variety of meningococcal strains. Two sub-families of serologically distinct...
10.
Green B, Zhang Y, Masi A, Barniak V, Wetherell M, Smith R, et al.
Infect Immun
. 2005 Jan;
73(2):981-9.
PMID: 15664941
The multivalent pneumococcal conjugate vaccine is effective against both systemic disease and otitis media caused by serotypes contained in the vaccine. However, serotypes not covered by the present conjugate vaccine...